22:
206:
Surgical resection of a tumor is one of the primary treatment modalities for cancer and can be curative especially for patients with early disease. However, there is evidence that tumor resection generates a permissive environment for tumor growth, in part, via host-mediated processes. As part of the
117:
and antibiotics, represent a major systemic therapeutic modality for many cancers. These agents induce death in rapidly dividing cells thus targeting tumor cells, but at the same time damaging healthy tissue. Consequently, non-malignant host cells activate wound healing and inflammatory mechanisms to
2007:
Curigliano, G.; Petit, J. Y.; Bertolini, F.; Colleoni, M.; Peruzzotti, G.; de Braud, F.; Gandini, S.; Giraldo, A.; Martella, S. (2005). "Systemic
Effects of Surgery: Quantitative Analysis of Circulating Basic Fibroblast Growth Factor (bFGF), Vascular Endothelial Growth Factor (VEGF) and Transforming
2059:
Langenberg, Marlies H.G.; Nijkamp, Maarten W.; Roodhart, Jeanine M.L.; Snoeren, Nikol; Tang, Terence; Shaked, Yuval; Hillegersberg, Richard van; Witteveen, Petronella O.; Vermaat, Joost S.P.; Kranenburg, Onno; Kerbel, Robert S.; Medema, Rene H.; Borel Rinkes, Inne H.M.; Voest, Emile E. (27 October
177:
that ensues activates a range of compensatory mechanisms that sustain vascularization, leading to resistance to the anti-angiogenic drug. Many of these compensatory mechanisms involve host cells. For example, treating tumor-bearing mice with vascular-disrupting agents (that specifically target
96:
and enzymes accompanied by acute mobilization and tumor homing of bone-marrow derived cells. These therapy-induced effects have the potential to facilitate tumor growth and spread, counteracting the beneficial effects of therapy. Thus, the host response to cancer therapy creates a paradoxical
1569:
Shojaei, Farbod; Wu, Xiumin; Zhong, Cuiling; Yu, Lanlan; Liang, Xiao-Huan; Yao, Jenny; Blanchard, Dominique; Bais, Carlos; Peale, Franklin V.; van
Bruggen, Nicholas; Ho, Calvin; Ross, Jed; Tan, Martha; Carano, Richard A. D.; Meng, Y. Gloria; Ferrara, Napoleone (December 2007). "Bv8 regulates
149:
is a well-established treatment modality for several cancer types. However, relapses after radiotherapy are often more aggressive and associated with poor prognosis. Cumulative evidence shows that the host response to radiotherapy is a contributing factor to this effect. Tumors implanted in
150:
pre-irradiated tissue grow with slower kinetics, however, paradoxically exhibit enhanced invasive and metastatic properties, a phenomenon known as the βtumor bed effectβ. This enhanced aggressiveness is attributed to radiation-induced modifications of the
1466:
Shojaei, Farbod; Wu, Xiumin; Malik, Ajay K; Zhong, Cuiling; Baldwin, Megan E; Schanz, Stefanie; Fuh, Germaine; Gerber, Hans-Peter; Ferrara, Napoleone (29 July 2007). "Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells".
83:
All cancer treatment modalities (e.g., chemotherapy, targeted drugs, radiation and surgery) trigger systemic and local effects in the treated subject (i.e., the host). These include a rapid elevation in the levels of circulating
74:
is defined as a physiological response of the non-malignant cells of the body (also known as host cells) to a specific cancer therapy. The response is therapy-specific, occurring independently of cancer type or stage.
97:
situation in which the desired therapeutic effect of treatment is reduced by its side effect on host cells. The balance between these two opposing activities determines the overall efficacy and outcome of treatment.
1966:
Bono, Anna; Bianchi, Paolo; Locatelli, Andrea; Calleri, Angelica; Quarna, Jessica; Antoniott, Pierluigi; Rabascio, Cristina; Mancuso, Patrizia; Andreoni, Bruno; Bertolini, Francesco (27 October 2014).
173:) target the blood vessels required for tumor survival. The rationale behind this strategy is to starve the tumor of oxygen and nutrients, limiting its ability to grow. However,
223:. For example, lungs are more prone to metastatic seeding after a surgical incision in the abdominal region of mice. This effect is due to increased expression and activity of
251:. Experimental studies have shown that combining conventional cancer therapies with agents that selectively block therapy-induced factors improves treatment efficacies.
1623:"Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects"
243:
Characterizing the host response to cancer therapy in patients has clinical implications especially in the field of personalized medicine (also known as
190:, and TIE2-expressing monocytes contribute to therapy resistance. In mouse tumor models, anti-angiogenic therapy causes an elevation in tumor-promoting
849:
Sofia Vala, I; Martins, L. R.; Imaizumi, N; Nunes, R. J.; Rino, J; Kuonen, F; Carvalho, L. M.; RΓΌegg, C; Grillo, I. M (2010). Gartel, Andrei L. (ed.).
437:
Voloshin, Tali; Voest, Emile E.; Shaked, Yuval (July 2013). "The host immunological response to cancer therapy: An emerging concept in tumor biology".
182:
that home to tumor margins where they facilitate revascularization. In addition, various types of pro-angiogenic bone marrow-derived cells such as
215:, extracellular matrix-modifying enzymes, and immune cells released during this process may also promote proliferation of residual tumor cells,
531:"Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing Agents"
227:(LOX), an extracellular matrix remodeling enzyme produced at the hypoxic surgical site. In clinical settings, elevated levels of circulating
918:"Matrix Metalloproteinase-9 Is Required for Tumor Vasculogenesis but Not for Angiogenesis: Role of Bone Marrow-Derived Myelomonocytic Cells"
1917:
Rachman-Tzemah, C; Zaffryar-Eilot, S; Grossman, M; Ribero, D; Timaner, M; MΓ€ki, J. M.; Myllyharju, J; Bertolini, F; Hershkovitz, D (2017).
802:"Molecular Pathways: Emerging Pathways Mediating Growth, Invasion, and Metastasis of Tumors Progressing in an Irradiated Microenvironment"
1621:
Zhang, W.; Zhu, X.-D.; Sun, H.-C.; Xiong, Y.-Q.; Zhuang, P.-Y.; Xu, H.-X.; Kong, L.-Q.; Wang, L.; Wu, W.-Z.; Tang, Z.-Y. (22 June 2010).
1024:"Inhibition of the Kit Ligand/c-Kit Axis Attenuates Metastasis in a Mouse Model Mimicking Local Breast Cancer Relapse after Radiotherapy"
639:"Host Response to Short-term, Single-Agent Chemotherapy Induces Matrix Metalloproteinase-9 Expression and Accelerates Metastasis in Mice"
1022:
Kuonen, F.; Laurent, J.; Secondini, C.; Lorusso, G.; Stehle, J.-C.; Rausch, T.; Faes-van't Hull, E.; Bieler, G.; Alghisi, G.-C. (2012).
686:
Karagiannis, G. S.; Pastoriza, J. M.; Wang, Y; Harney, A. S.; Entenberg, D; Pignatelli, J; Sharma, V. P.; Xue, E. A.; Cheng, E (2017).
637:
Gingis-Velitski, S.; Loven, D.; Benayoun, L.; Munster, M.; Bril, R.; Voloshin, T.; Alishekevitz, D.; Bertolini, F.; Shaked, Y. (2011).
1187:
Okubo, Makiko; Kioi, Mitomu; Nakashima, Hideyuki; Sugiura, Kei; Mitsudo, Kenji; Aoki, Ichiro; Taniguchi, Hideki; Tohnai, Iwai (2016).
1811:"Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy"
1071:
Timaner, M; Bril, R; Kaidar-Person, O; Rachman-Tzemah, C; Alishekevitz, D; Kotsofruk, R; Miller, V; Nevelsky, A; Daniel, S (2015).
183:
118:
repair chemotherapy-induced damage. These repair mechanisms have the potential to exacerbate tumor promoting processes such as
1512:"G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models"
274:
Shaked, Yuval (26 April 2016). "Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects".
1415:
Shaked, Y. (22 September 2006). "Therapy-Induced Acute
Recruitment of Circulating Endothelial Progenitor Cells to Tumors".
529:
Shaked, Y; Henke, E; Roodhart, J. M.L.; Mancuso, P; Langenberg, M. H.G.; Colleoni, M; Daenen, L. G.; Man, S; Xu, P (2008).
2062:"Liver surgery induces an immediate mobilization of progenitor cells in liver cancer patients: A potential role for G-CSF"
580:"Stress-inducible gene Atf3 in the noncancer host cells contributes to chemotherapy-exacerbated breast cancer metastasis"
1128:
Chiang, Chi-Shiun; Fu, Sheng Yung; Wang, Shu-Chi; Yu, Ching-Fang; Chen, Fang-Hsin; Lin, Chi-Min; Hong, Ji-Hong (2012).
967:"Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice"
228:
207:
wound healing process, surgical tissue trauma is rapidly followed by a cascade of inflammatory processes. Many of the
187:
179:
127:
2106:
1762:"Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis"
130:
that home to the tumor site where they promote angiogenesis. In addition, a variety of immune cell types, such as
1252:
Seifert, L; Werba, G; Tiwari, S; Giao Ly, N. N; Nguy, S; Alothman, S; Alqunaibit, D; Avanzi, A; Daley, D (2016).
1189:"M2-polarized macrophages contribute to neovasculogenesis, leading to relapse of oral cancer following radiation"
1760:
PΓ ez-Ribes, M; Allen, E; Hudock, J; Takeda, T; Okuyama, H; ViΓ±als, F; Inoue, M; Bergers, G; Hanahan, D (2009).
131:
1360:"Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy"
1968:"Angiogenic cells, macroparticles and RNA transcripts in laparoscopic vs open surgery for colorectal cancer"
743:
Arnold, K. M; Flynn, N. J; Raben, A; Romak, L; Yu, Y; Dicker, A. P; Mourtada, F; Sims-Mourtada, J (2018).
170:
151:
138:, are recruited to the tumor site in a chemotherapy-dependent manner, an effect that enhances metastasis.
402:
Katz, Ofrat Beyar; Shaked, Yuval (March 2015). "Host effects contributing to cancer therapy resistance".
235:
and tumor progression have been reported in response to major surgery in comparison to minimal surgery.
2008:
Growth Factor Beta (TGF-Ξ²) in
Patients with Breast Cancer Who Underwent Limited or Extended Surgery".
1254:"Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice"
320:
Daenen, L G M; Houthuijzen, J M; Cirkel, G A; Roodhart, J M L; Shaked, Y; Voest, E E (25 March 2013).
51:
1822:
1711:
Ebos, J.M.L.; Lee, C. R.; Cruz-Munoz, W; Bjarnason, G. A.; Christensen, J. G.; Kerbel, R. S. (2009).
1579:
1523:
1510:
Shojaei, F.; Wu, X.; Qu, X.; Kowanetz, M.; Yu, L.; Tan, M.; Meng, Y. G.; Ferrara, N. (3 April 2009).
1424:
1200:
862:
745:"The Impact of Radiation on the Tumor Microenvironment: Effect of Dose and Fractionation Schedules"
248:
32:
2041:
1713:"Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis"
1603:
1492:
1448:
299:
244:
126:. In mouse tumor models, different chemotherapy types induce a rapid mobilization of circulating
851:"Low Doses of Ionizing Radiation Promote Tumor Growth and Metastasis by Enhancing Angiogenesis"
2083:
2033:
2025:
1989:
1948:
1899:
1858:
1840:
1791:
1742:
1693:
1685:
1644:
1595:
1551:
1484:
1440:
1397:
1379:
1340:
1322:
1283:
1234:
1216:
1169:
1151:
1110:
1092:
1053:
1045:
1004:
986:
947:
898:
880:
831:
823:
782:
764:
725:
707:
668:
660:
619:
601:
560:
511:
493:
454:
419:
384:
343:
291:
146:
688:"Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism"
2073:
2017:
1979:
1938:
1930:
1889:
1848:
1830:
1781:
1773:
1732:
1724:
1675:
1664:"Tie2-Expressing Monocytes and Tumor Angiogenesis: Regulation by Hypoxia and Angiopoietin-2"
1634:
1587:
1541:
1531:
1476:
1432:
1387:
1371:
1330:
1314:
1273:
1265:
1224:
1208:
1159:
1141:
1100:
1084:
1035:
994:
978:
937:
929:
888:
870:
813:
772:
756:
715:
699:
650:
609:
591:
550:
542:
501:
485:
446:
411:
374:
333:
283:
322:"Treatment-induced host-mediated mechanisms reducing the efficacy of antitumor therapies"
1919:"Blocking Surgically Induced Lysyl Oxidase Activity Reduces the Risk of Lung Metastases"
1826:
1583:
1527:
1428:
1204:
866:
1943:
1918:
1853:
1810:
1809:
Ebos, J. M. L.; Lee, C. R.; Christensen, J. G.; Mutsaers, A. J.; Kerbel, R. S. (2007).
1786:
1761:
1737:
1712:
1546:
1511:
1392:
1359:
1335:
1302:
1278:
1253:
1229:
1188:
1164:
1129:
1105:
1072:
999:
966:
942:
917:
893:
850:
777:
744:
720:
687:
614:
579:
555:
530:
506:
473:
114:
2100:
1894:
1877:
224:
208:
195:
174:
93:
2045:
1452:
303:
1878:"Surgery, wound healing, and metastasis: Recent insights and clinical implications"
1607:
1496:
232:
216:
155:
119:
110:
1680:
1663:
1639:
1622:
1375:
1040:
1023:
818:
801:
655:
638:
379:
362:
1934:
1269:
965:
Kioi, M; Vogel, H; Schultz, G; Hoffman, R. M.; Harsh, G. R.; Brown, J. M (2010).
875:
703:
1303:"Antiangiogenic therapy: impact on invasion, disease progression and metastasis"
450:
415:
231:, bone marrow-derived cells as well as circulating factors with known roles in
2021:
1777:
1728:
1318:
933:
546:
489:
287:
220:
159:
135:
123:
2029:
1844:
1689:
1383:
1326:
1220:
1155:
1096:
1088:
1049:
990:
884:
827:
768:
760:
711:
664:
605:
497:
474:"Chemotherapy-induced metastasis: mechanisms and translational opportunities"
1835:
1536:
1436:
1146:
1073:"Dequalinium blocks macrophage-induced metastasis following local radiation"
596:
89:
41:
2087:
2037:
1993:
1984:
1967:
1952:
1903:
1862:
1795:
1746:
1697:
1648:
1599:
1555:
1488:
1444:
1401:
1344:
1287:
1238:
1173:
1114:
1057:
1008:
951:
902:
835:
786:
729:
672:
623:
564:
515:
458:
423:
388:
347:
295:
21:
2078:
2061:
363:"Prodding the Beast: Assessing the Impact of Treatment-Induced Metastasis"
212:
191:
85:
1591:
338:
321:
178:
tumor-associated vessels) triggers an acute mobilization of circulating
1212:
198:
that in turn augment the invasive and metastatic potential of tumors.
982:
1480:
1130:"Irradiation Promotes an M2 Macrophage Phenotype in Tumor Hypoxia"
578:
Chang, Y. S; Jalgaonkar, S. P.; Middleton, J. D.; Hai, T (2017).
15:
472:
Karagiannis, G. S.; Condeelis, J. S.; Oktay, M. H. (2018).
101:
Host response to different treatment modalities for cancer
158:
and recruitment of pro-metastatic bone marrow cells and
113:, including alkylating agents, microtubule inhibitors,
46:
36:
1358:Ebos, J. M. L.; Lee, C. R.; Kerbel, R. S. (2009).
1662:Lewis, C. E.; De Palma, M.; Naldini, L. (2007).
1815:Proceedings of the National Academy of Sciences
1516:Proceedings of the National Academy of Sciences
584:Proceedings of the National Academy of Sciences
1570:myeloid-cell-dependent tumour angiogenesis".
800:Kuonen, F.; Secondini, C.; Ruegg, C. (2012).
8:
2077:
1983:
1942:
1893:
1852:
1834:
1785:
1736:
1679:
1638:
1545:
1535:
1391:
1334:
1277:
1228:
1163:
1145:
1104:
1039:
998:
941:
892:
874:
817:
776:
719:
654:
613:
595:
554:
505:
378:
337:
1876:Ceelen, W; Pattyn, P; Mareel, M (2014).
1882:Critical Reviews in Oncology/Hematology
259:
1301:Ebos, J. M. L.; Kerbel, R. S. (2011).
478:Clinical & Experimental Metastasis
165:Host response to anti-angiogenic drugs
7:
2010:Breast Cancer Research and Treatment
315:
313:
269:
267:
265:
263:
142:Host response to radiation therapy
14:
971:Journal of Clinical Investigation
1895:10.1016/j.critrevonc.2013.07.008
1307:Nature Reviews Clinical Oncology
276:Nature Reviews Clinical Oncology
184:myeloid-derived suppressor cells
20:
916:Ahn, G. O; Brown, J. M (2008).
361:Ebos, J. M. L. (30 July 2015).
72:host response to cancer therapy
692:Science Translational Medicine
1:
1681:10.1158/0008-5472.CAN-07-1684
1640:10.1158/1078-0432.CCR-09-2904
1376:10.1158/1078-0432.CCR-09-0095
1041:10.1158/1078-0432.CCR-11-3028
819:10.1158/1078-0432.CCR-11-1758
656:10.1158/0008-5472.CAN-11-0629
380:10.1158/0008-5472.CAN-15-0308
106:Host response to chemotherapy
2066:Cancer Biology & Therapy
1972:Cancer Biology & Therapy
1935:10.1016/j.celrep.2017.04.005
1270:10.1053/j.gastro.2016.02.070
876:10.1371/journal.pone.0011222
749:Cancer Growth and Metastasis
704:10.1126/scitranslmed.aan0026
229:endothelial progenitor cells
188:tumor-associated macrophages
180:endothelial progenitor cells
128:endothelial progenitor cells
451:10.1016/j.yexcr.2013.03.007
2123:
439:Experimental Cell Research
416:10.1016/j.drup.2014.12.002
169:Anti-angiogenic drugs (or
2022:10.1007/s10549-005-3381-1
1778:10.1016/j.ccr.2009.01.027
1729:10.1016/j.ccr.2009.01.021
1319:10.1038/nrclinonc.2011.21
934:10.1016/j.ccr.2007.11.032
547:10.1016/j.ccr.2008.08.001
490:10.1007/s10585-017-9870-x
288:10.1038/nrclinonc.2016.57
1627:Clinical Cancer Research
1364:Clinical Cancer Research
1089:10.18632/oncotarget.4826
1028:Clinical Cancer Research
806:Clinical Cancer Research
761:10.1177/1179064418761639
202:Host response to surgery
1836:10.1073/pnas.0708148104
1537:10.1073/pnas.0902280106
1437:10.1126/science.1127592
1147:10.3389/fonc.2012.00089
597:10.1073/pnas.1700455114
404:Drug Resistance Updates
171:angiogenesis inhibitors
35:, as no other articles
1985:10.4161/cbt.10.7.12898
152:tumor microenvironment
2079:10.4161/cbt.9.9.11551
1134:Frontiers in Oncology
239:Clinical implications
154:, including enhanced
1469:Nature Biotechnology
1827:2007PNAS..10417069E
1821:(43): 17069β17074.
1592:10.1038/nature06348
1584:2007Natur.450..825S
1528:2009PNAS..106.6742S
1429:2006Sci...313.1785S
1423:(5794): 1785β1787.
1264:(7): 1659β1672.e5.
1205:2016NatSR...627548O
867:2010PLoSO...511222S
755:: 117906441876163.
590:(34): E7159βE7168.
339:10.1038/onc.2013.94
249:biomarker discovery
132:myeloid progenitors
1193:Scientific Reports
245:precision medicine
54:for suggestions.
44:to this page from
2107:Cancer treatments
1674:(18): 8429β8432.
1633:(13): 3420β3430.
1578:(7171): 825β831.
1522:(16): 6742β6747.
1370:(16): 5020β5025.
1213:10.1038/srep27548
1034:(16): 4365β4374.
812:(19): 5196β5202.
698:(397): eaan0026.
649:(22): 6986β6996.
445:(11): 1687β1695.
373:(17): 3427β3435.
332:(11): 1341β1347.
68:
67:
2114:
2092:
2091:
2081:
2056:
2050:
2049:
2004:
1998:
1997:
1987:
1963:
1957:
1956:
1946:
1914:
1908:
1907:
1897:
1873:
1867:
1866:
1856:
1838:
1806:
1800:
1799:
1789:
1757:
1751:
1750:
1740:
1708:
1702:
1701:
1683:
1659:
1653:
1652:
1642:
1618:
1612:
1611:
1566:
1560:
1559:
1549:
1539:
1507:
1501:
1500:
1463:
1457:
1456:
1412:
1406:
1405:
1395:
1355:
1349:
1348:
1338:
1298:
1292:
1291:
1281:
1258:Gastroenterology
1249:
1243:
1242:
1232:
1184:
1178:
1177:
1167:
1149:
1125:
1119:
1118:
1108:
1083:(29): 27537β54.
1068:
1062:
1061:
1043:
1019:
1013:
1012:
1002:
983:10.1172/JCI40283
962:
956:
955:
945:
913:
907:
906:
896:
878:
846:
840:
839:
821:
797:
791:
790:
780:
740:
734:
733:
723:
683:
677:
676:
658:
634:
628:
627:
617:
599:
575:
569:
568:
558:
526:
520:
519:
509:
469:
463:
462:
434:
428:
427:
399:
393:
392:
382:
358:
352:
351:
341:
317:
308:
307:
271:
63:
60:
49:
47:related articles
24:
16:
2122:
2121:
2117:
2116:
2115:
2113:
2112:
2111:
2097:
2096:
2095:
2058:
2057:
2053:
2006:
2005:
2001:
1965:
1964:
1960:
1916:
1915:
1911:
1875:
1874:
1870:
1808:
1807:
1803:
1759:
1758:
1754:
1710:
1709:
1705:
1668:Cancer Research
1661:
1660:
1656:
1620:
1619:
1615:
1568:
1567:
1563:
1509:
1508:
1504:
1481:10.1038/nbt1323
1465:
1464:
1460:
1414:
1413:
1409:
1357:
1356:
1352:
1300:
1299:
1295:
1251:
1250:
1246:
1186:
1185:
1181:
1127:
1126:
1122:
1070:
1069:
1065:
1021:
1020:
1016:
964:
963:
959:
915:
914:
910:
848:
847:
843:
799:
798:
794:
742:
741:
737:
685:
684:
680:
643:Cancer Research
636:
635:
631:
577:
576:
572:
528:
527:
523:
471:
470:
466:
436:
435:
431:
401:
400:
396:
367:Cancer Research
360:
359:
355:
319:
318:
311:
282:(10): 611β626.
273:
272:
261:
257:
241:
204:
167:
144:
115:antimetabolites
108:
103:
81:
64:
58:
55:
45:
42:introduce links
25:
12:
11:
5:
2120:
2118:
2110:
2109:
2099:
2098:
2094:
2093:
2072:(9): 743β748.
2051:
1999:
1978:(7): 682β685.
1958:
1929:(4): 774β784.
1909:
1868:
1801:
1772:(3): 220β231.
1752:
1723:(3): 232β239.
1703:
1654:
1613:
1561:
1502:
1475:(8): 911β920.
1458:
1407:
1350:
1313:(4): 210β221.
1293:
1244:
1179:
1120:
1063:
1014:
977:(3): 694β705.
957:
928:(3): 193β205.
908:
841:
792:
735:
678:
629:
570:
541:(3): 263β273.
521:
484:(4): 269β284.
464:
429:
394:
353:
309:
258:
256:
253:
240:
237:
209:growth factors
203:
200:
196:growth factors
166:
163:
143:
140:
111:Chemotherapies
107:
104:
102:
99:
94:growth factors
80:
77:
66:
65:
52:Find link tool
28:
26:
19:
13:
10:
9:
6:
4:
3:
2:
2119:
2108:
2105:
2104:
2102:
2089:
2085:
2080:
2075:
2071:
2067:
2063:
2055:
2052:
2047:
2043:
2039:
2035:
2031:
2027:
2023:
2019:
2015:
2011:
2003:
2000:
1995:
1991:
1986:
1981:
1977:
1973:
1969:
1962:
1959:
1954:
1950:
1945:
1940:
1936:
1932:
1928:
1924:
1920:
1913:
1910:
1905:
1901:
1896:
1891:
1887:
1883:
1879:
1872:
1869:
1864:
1860:
1855:
1850:
1846:
1842:
1837:
1832:
1828:
1824:
1820:
1816:
1812:
1805:
1802:
1797:
1793:
1788:
1783:
1779:
1775:
1771:
1767:
1763:
1756:
1753:
1748:
1744:
1739:
1734:
1730:
1726:
1722:
1718:
1714:
1707:
1704:
1699:
1695:
1691:
1687:
1682:
1677:
1673:
1669:
1665:
1658:
1655:
1650:
1646:
1641:
1636:
1632:
1628:
1624:
1617:
1614:
1609:
1605:
1601:
1597:
1593:
1589:
1585:
1581:
1577:
1573:
1565:
1562:
1557:
1553:
1548:
1543:
1538:
1533:
1529:
1525:
1521:
1517:
1513:
1506:
1503:
1498:
1494:
1490:
1486:
1482:
1478:
1474:
1470:
1462:
1459:
1454:
1450:
1446:
1442:
1438:
1434:
1430:
1426:
1422:
1418:
1411:
1408:
1403:
1399:
1394:
1389:
1385:
1381:
1377:
1373:
1369:
1365:
1361:
1354:
1351:
1346:
1342:
1337:
1332:
1328:
1324:
1320:
1316:
1312:
1308:
1304:
1297:
1294:
1289:
1285:
1280:
1275:
1271:
1267:
1263:
1259:
1255:
1248:
1245:
1240:
1236:
1231:
1226:
1222:
1218:
1214:
1210:
1206:
1202:
1198:
1194:
1190:
1183:
1180:
1175:
1171:
1166:
1161:
1157:
1153:
1148:
1143:
1139:
1135:
1131:
1124:
1121:
1116:
1112:
1107:
1102:
1098:
1094:
1090:
1086:
1082:
1078:
1074:
1067:
1064:
1059:
1055:
1051:
1047:
1042:
1037:
1033:
1029:
1025:
1018:
1015:
1010:
1006:
1001:
996:
992:
988:
984:
980:
976:
972:
968:
961:
958:
953:
949:
944:
939:
935:
931:
927:
923:
919:
912:
909:
904:
900:
895:
890:
886:
882:
877:
872:
868:
864:
861:(6): e11222.
860:
856:
852:
845:
842:
837:
833:
829:
825:
820:
815:
811:
807:
803:
796:
793:
788:
784:
779:
774:
770:
766:
762:
758:
754:
750:
746:
739:
736:
731:
727:
722:
717:
713:
709:
705:
701:
697:
693:
689:
682:
679:
674:
670:
666:
662:
657:
652:
648:
644:
640:
633:
630:
625:
621:
616:
611:
607:
603:
598:
593:
589:
585:
581:
574:
571:
566:
562:
557:
552:
548:
544:
540:
536:
532:
525:
522:
517:
513:
508:
503:
499:
495:
491:
487:
483:
479:
475:
468:
465:
460:
456:
452:
448:
444:
440:
433:
430:
425:
421:
417:
413:
409:
405:
398:
395:
390:
386:
381:
376:
372:
368:
364:
357:
354:
349:
345:
340:
335:
331:
327:
323:
316:
314:
310:
305:
301:
297:
293:
289:
285:
281:
277:
270:
268:
266:
264:
260:
254:
252:
250:
246:
238:
236:
234:
230:
226:
225:lysyl oxidase
222:
218:
214:
210:
201:
199:
197:
193:
189:
185:
181:
176:
175:tumor hypoxia
172:
164:
162:
161:
157:
153:
148:
141:
139:
137:
133:
129:
125:
121:
116:
112:
105:
100:
98:
95:
91:
87:
78:
76:
73:
62:
53:
48:
43:
39:
38:
34:
29:This article
27:
23:
18:
17:
2069:
2065:
2054:
2016:(1): 35β40.
2013:
2009:
2002:
1975:
1971:
1961:
1926:
1923:Cell Reports
1922:
1912:
1888:(1): 16β26.
1885:
1881:
1871:
1818:
1814:
1804:
1769:
1765:
1755:
1720:
1716:
1706:
1671:
1667:
1657:
1630:
1626:
1616:
1575:
1571:
1564:
1519:
1515:
1505:
1472:
1468:
1461:
1420:
1416:
1410:
1367:
1363:
1353:
1310:
1306:
1296:
1261:
1257:
1247:
1199:(1): 27548.
1196:
1192:
1182:
1137:
1133:
1123:
1080:
1076:
1066:
1031:
1027:
1017:
974:
970:
960:
925:
921:
911:
858:
854:
844:
809:
805:
795:
752:
748:
738:
695:
691:
681:
646:
642:
632:
587:
583:
573:
538:
534:
524:
481:
477:
467:
442:
438:
432:
407:
403:
397:
370:
366:
356:
329:
325:
279:
275:
242:
233:angiogenesis
217:angiogenesis
205:
168:
156:angiogenesis
147:Radiotherapy
145:
120:angiogenesis
109:
82:
71:
69:
56:
30:
1766:Cancer Cell
1717:Cancer Cell
922:Cancer Cell
535:Cancer Cell
160:macrophages
136:macrophages
59:August 2023
1077:Oncotarget
255:References
221:metastasis
134: and
124:metastasis
90:chemokines
79:Background
50:; try the
37:link to it
2030:0167-6806
1845:0027-8424
1690:0008-5472
1384:1078-0432
1327:1759-4774
1221:2045-2322
1156:2234-943X
1097:1949-2553
1050:1078-0432
991:0021-9738
885:1932-6203
828:1078-0432
769:1179-0644
712:1946-6234
665:0008-5472
606:0027-8424
498:0262-0898
410:: 33β42.
213:cytokines
192:cytokines
86:cytokines
40:. Please
2101:Category
2088:20215863
2046:11619834
2038:16184456
1994:20676027
1953:28445728
1904:23958676
1863:17942672
1796:19249680
1747:19249681
1698:17875679
1649:20570927
1600:18064003
1556:19346489
1489:17664940
1453:43494176
1445:16990548
1402:19671869
1345:21364524
1288:26946344
1239:27271009
1174:22888475
1115:26348470
1058:22711708
1009:20179352
952:18328424
903:20574535
855:PLOS ONE
836:22730447
787:29551910
730:28679654
673:21978934
624:28784776
565:18772115
516:29307118
459:23518388
424:25575621
389:26229121
348:23524584
326:Oncogene
304:37788179
296:27118493
2060:2014).
1944:5413586
1854:2040401
1823:Bibcode
1787:2874829
1738:4540346
1608:4420372
1580:Bibcode
1547:2665197
1524:Bibcode
1497:6524573
1425:Bibcode
1417:Science
1393:2743513
1336:4540336
1279:4909514
1230:4897643
1201:Bibcode
1165:3412458
1106:4695007
1000:2827954
943:2967441
894:2888592
863:Bibcode
778:5846913
721:5592784
615:5576783
556:2565587
507:6035114
2086:
2044:
2036:
2028:
1992:
1951:
1941:
1902:
1861:
1851:
1843:
1794:
1784:
1745:
1735:
1696:
1688:
1647:
1606:
1598:
1572:Nature
1554:
1544:
1495:
1487:
1451:
1443:
1400:
1390:
1382:
1343:
1333:
1325:
1286:
1276:
1237:
1227:
1219:
1172:
1162:
1154:
1140:: 89.
1113:
1103:
1095:
1056:
1048:
1007:
997:
989:
950:
940:
901:
891:
883:
834:
826:
785:
775:
767:
728:
718:
710:
671:
663:
622:
612:
604:
563:
553:
514:
504:
496:
457:
422:
387:
346:
302:
294:
247:) and
33:orphan
31:is an
2042:S2CID
1604:S2CID
1493:S2CID
1449:S2CID
300:S2CID
2084:PMID
2034:PMID
2026:ISSN
1990:PMID
1949:PMID
1900:PMID
1859:PMID
1841:ISSN
1792:PMID
1743:PMID
1694:PMID
1686:ISSN
1645:PMID
1596:PMID
1552:PMID
1485:PMID
1441:PMID
1398:PMID
1380:ISSN
1341:PMID
1323:ISSN
1284:PMID
1235:PMID
1217:ISSN
1170:PMID
1152:ISSN
1111:PMID
1093:ISSN
1054:PMID
1046:ISSN
1005:PMID
987:ISSN
948:PMID
899:PMID
881:ISSN
832:PMID
824:ISSN
783:PMID
765:ISSN
726:PMID
708:ISSN
669:PMID
661:ISSN
620:PMID
602:ISSN
561:PMID
512:PMID
494:ISSN
455:PMID
420:PMID
385:PMID
344:PMID
292:PMID
219:and
194:and
122:and
70:The
2074:doi
2018:doi
1980:doi
1939:PMC
1931:doi
1890:doi
1849:PMC
1831:doi
1819:104
1782:PMC
1774:doi
1733:PMC
1725:doi
1676:doi
1635:doi
1588:doi
1576:450
1542:PMC
1532:doi
1520:106
1477:doi
1433:doi
1421:313
1388:PMC
1372:doi
1331:PMC
1315:doi
1274:PMC
1266:doi
1262:150
1225:PMC
1209:doi
1160:PMC
1142:doi
1101:PMC
1085:doi
1036:doi
995:PMC
979:doi
975:120
938:PMC
930:doi
889:PMC
871:doi
814:doi
773:PMC
757:doi
716:PMC
700:doi
651:doi
610:PMC
592:doi
588:114
551:PMC
543:doi
502:PMC
486:doi
447:doi
443:319
412:doi
375:doi
334:doi
284:doi
2103::
2082:.
2068:.
2064:.
2040:.
2032:.
2024:.
2014:93
2012:.
1988:.
1976:10
1974:.
1970:.
1947:.
1937:.
1927:19
1925:.
1921:.
1898:.
1886:89
1884:.
1880:.
1857:.
1847:.
1839:.
1829:.
1817:.
1813:.
1790:.
1780:.
1770:15
1768:.
1764:.
1741:.
1731:.
1721:15
1719:.
1715:.
1692:.
1684:.
1672:67
1670:.
1666:.
1643:.
1631:16
1629:.
1625:.
1602:.
1594:.
1586:.
1574:.
1550:.
1540:.
1530:.
1518:.
1514:.
1491:.
1483:.
1473:25
1471:.
1447:.
1439:.
1431:.
1419:.
1396:.
1386:.
1378:.
1368:15
1366:.
1362:.
1339:.
1329:.
1321:.
1309:.
1305:.
1282:.
1272:.
1260:.
1256:.
1233:.
1223:.
1215:.
1207:.
1195:.
1191:.
1168:.
1158:.
1150:.
1136:.
1132:.
1109:.
1099:.
1091:.
1079:.
1075:.
1052:.
1044:.
1032:18
1030:.
1026:.
1003:.
993:.
985:.
973:.
969:.
946:.
936:.
926:13
924:.
920:.
897:.
887:.
879:.
869:.
857:.
853:.
830:.
822:.
810:18
808:.
804:.
781:.
771:.
763:.
753:11
751:.
747:.
724:.
714:.
706:.
694:.
690:.
667:.
659:.
647:71
645:.
641:.
618:.
608:.
600:.
586:.
582:.
559:.
549:.
539:14
537:.
533:.
510:.
500:.
492:.
482:35
480:.
476:.
453:.
441:.
418:.
408:19
406:.
383:.
371:75
369:.
365:.
342:.
330:33
328:.
324:.
312:^
298:.
290:.
280:13
278:.
262:^
211:,
186:,
92:,
88:,
2090:.
2076::
2070:9
2048:.
2020::
1996:.
1982::
1955:.
1933::
1906:.
1892::
1865:.
1833::
1825::
1798:.
1776::
1749:.
1727::
1700:.
1678::
1651:.
1637::
1610:.
1590::
1582::
1558:.
1534::
1526::
1499:.
1479::
1455:.
1435::
1427::
1404:.
1374::
1347:.
1317::
1311:8
1290:.
1268::
1241:.
1211::
1203::
1197:6
1176:.
1144::
1138:2
1117:.
1087::
1081:6
1060:.
1038::
1011:.
981::
954:.
932::
905:.
873::
865::
859:5
838:.
816::
789:.
759::
732:.
702::
696:9
675:.
653::
626:.
594::
567:.
545::
518:.
488::
461:.
449::
426:.
414::
391:.
377::
350:.
336::
306:.
286::
61:)
57:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
